Your Location:Home >Products >Compound >224785-90-4

pd_meltingpoint:230-235 °C
Appearance:White crystalline powder
Purity:99%
Quality products make an important contribution to long-term revenue and profitability. Buy cost-effective 99% pure Vardenafil 224785-90-4 now
Vardenafil Hydrochloride Trihydrate (cas# 330808-88-3) has therapeutic applications and used in cosmetics and personal care products.
4-ethylpiperazine
2-(2-ethoxy-phenyl)-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one
vardenafil
| Conditions | Yield |
|---|---|
|
2-(2-ethoxy-phenyl)-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
With
chlorosulfonic acid;
at 0 - 22 ℃;
for 0.75h;
4-ethylpiperazine;
In
dichloromethane;
at -3 - 25 ℃;
for 0.75h;
Product distribution / selectivity;
|
4-ethylpiperazine
4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenelsulfonic acid chloride
vardenafil
| Conditions | Yield |
|---|---|
|
In
dichloromethane;
|
The CAS number of Vardenafil hydrochloride trihydrate is 224785-90-4.
More information of Vardenafil hydrochloride trihydrate 224785-90-4 are:
|
CAS Number |
224785-90-4 |
|
Density |
1.37 g/cm3 |
|
Melting Point |
230-235 °C |
|
Boiling Point |
692.2 °C at 760 mmHg |
|
Flash Point |
372.5 °C |
|
Vapor Pressure |
5.17E-19mmHg at 25°C |
|
PSA |
121.28000 |
|
LogP |
4.63100 |
|
Pka |
9.86±0.20(Predicted) |
Synonyms for Vardenafil hydrochloride trihydrate 224785-90-4:Piperazine,1-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl-(9CI);2-[2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;Nuviva;BAY 38-9456;1-((3-(3,4-Dihydro-5-methyl-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine;Vivanza;
The chemical formula of Vardenafil hydrochloride trihydrate is C23H32N6O4S which containing 23 Carbon atoms,32 Hydrogen atoms,6 Nitrogen atoms,4 Oxygen atoms and 1 Sulfur atoms,and the molecular weight of Vardenafil hydrochloride trihydrate is 488.611.
Vardenafil is a new PDE5 inhibitor launched for oral treatment of male erectile dysfunction and it has significant structural similarity with sildenafil (Viagra?), which was the first PDE5 inhibitor introduced in 1998 for this indication. Vardenafil is synthesized in three steps starting with a cyclization reaction of 2-ethyoxybenzamidine with 2-butyramidopropionic acid and ethoxyallyl chloride to construct the imidazotriazine ring system, followed by sulfonation to the corresponding sulfonyl chloride and subsequent condensation with 1-ethylpiperazine. The potency of PDE5 inhibition by vardenafil (IC50=0.7 nM) is ~10 times greater than that of sildenafil (IC50=6.6 nM). Vardenafil is typically administered in single doses of 10 and 20 mg. The time to reach maximum plasma concentration is 0.75 h, which is slightly shorter than those of sildenafil (tmax=1.16 h) and tadalafil (tmax=2h), and the half-life is 4–5 h. Although it is almost completely absorbed following oral administration, the mean absolute bioavailability of a 10 mg dose is ~15%, resulting from extensive first pass metabolism. Vardenafil is metabolized in the liver primarily by CYP3A4 and is eliminated mainly in feces. In clinical studies, 10–20 mg doses of vardenafil was well tolerated and efficacious in patients with ED of various severities, including subjects with comorbidities such as diabetes mellitus or hypertension or hyperlipidemia. The side-effect profile of vardenafil is similar to that of sildenafil, with headache, flushing, dyspepsia and nasal congestion being the most common adverse events. Vardenafil has systemic vasodilatory properties, which can cause transient decrease in supine blood pressure; however, it does not appear to translate into clinical effects. The mean maximum decreases in supine systolic blood pressure following 20 and 40 mg vardenafil were 6.9 and 4.3 mmHg, respectively, when compared to placebo. However, single and multiple oral doses of vardenafil up to 40 mg produced no clinically relevant changes in the ECGs of normal male volunteers.
InChI:InChI=1/C23H32N6O4S.ClH.3H2O/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28;;;;/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30);1H;3*1H2
Relevant articles related to Vardenafil hydrochloride trihydrate:
|
Article |
Source |
|
Synthesis and spectral characterization of related substances of vardenafil, an erectile dysfunction drug |
Reddy, Vajrala Venkata,Naga Brahmeswara Rao, Mandava Venkata,Reddy, Ghanta Mahesh,Mukkanti, Khagga,Reddy, Ganta Madhusudhan experimental part, p. 3513 - 3523 (2012/10/18) |
|
A PROCESS FOR THE PREPARATION AND ISOLATION OF VARDENAFIL AND SALTS THEREOF |
- Page/Page column 11, (2011/07/30) |
Zibo Yurui Biotechnology Co., Ltd is a quality supplier of Vardenafil hydrochloride trihydrate. Our main goal is customer satisfaction. Contact us to negotiate the best price for your business on Vardenafil hydrochloride trihydrate 224785-90-4.
CAS:50-56-6
CAS:224785-91-5
CAS:99181-50-7
CAS:6564-72-3